Synonym
EC-5026; EC 5026; EC5026; BPN-19186; BPN 19186; BPN19186;
IUPAC/Chemical Name
(S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea
InChi Key
LHRXHTKENPCGSZ-NSHDSACASA-N
InChi Code
InChI=1S/C18H23F4N3O3/c1-3-11(2)16(26)25-8-6-12(7-9-25)23-17(27)24-13-4-5-15(14(19)10-13)28-18(20,21)22/h4-5,10-12H,3,6-9H2,1-2H3,(H2,23,24,27)/t11-/m0/s1
SMILES Code
O=C(NC1CCN(C([C@@H](C)CC)=O)CC1)NC2=CC=C(OC(F)(F)F)C(F)=C2
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
EC5026 (BPN-19186) is a non-opioid and soluble Epoxide Hydrolase (sEH) inhibitor.
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
250.0 |
616.69 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
405.39
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Takeshita AA, Hammock BD, Wagner KM. Soluble epoxide hydrolase inhibition alleviates chemotherapy induced neuropathic pain. Front Pain Res (Lausanne). 2023 Jan 9;3:1100524. doi: 10.3389/fpain.2022.1100524. PMID: 36700145; PMCID: PMC9868926.
2: Du F, Cao R, Chen L, Sun J, Shi Y, Fu Y, Hammock BD, Zheng Z, Liu Z, Chen G. Structure-guided discovery of potent and oral soluble epoxide hydrolase inhibitors for the treatment of neuropathic pain. Acta Pharm Sin B. 2022 Mar;12(3):1377-1389. doi: 10.1016/j.apsb.2021.09.018. Epub 2021 Sep 22. PMID: 35530144; PMCID: PMC9072249.
3: Singh N, Li D, McReynolds CB, Morisseau C, Hammock BD. Improved ELISA for linoleate-derived diols in human plasma utilizing a polyHRP-based secondary tracer. Anal Methods. 2022 May 13;14(18):1810-1819. doi: 10.1039/d2ay00272h. PMID: 35481804; PMCID: PMC9116231.
4: Codony S, Calvó-Tusell C, Valverde E, Osuna S, Morisseau C, Loza MI, Brea J, Pérez C, Rodríguez-Franco MI, Pizarro-Delgado J, Corpas R, Griñán-Ferré C, Pallàs M, Sanfeliu C, Vázquez-Carrera M, Hammock BD, Feixas F, Vázquez S. From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis. J Med Chem. 2021 May 13;64(9):5429-5446. doi: 10.1021/acs.jmedchem.0c01601. Epub 2021 May 4. PMID: 33945278; PMCID: PMC8634379.
5: Hammock BD, McReynolds CB, Wagner K, Buckpitt A, Cortes-Puch I, Croston G, Lee KSS, Yang J, Schmidt WK, Hwang SH. Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative. J Med Chem. 2021 Feb 25;64(4):1856-1872. doi: 10.1021/acs.jmedchem.0c01886. Epub 2021 Feb 7. PMID: 33550801; PMCID: PMC7917437.
